Introduction
Verelan PM, a calcium channel blocker in the form of extended-release capsules, is primarily indicated for the treatment of hypertension to lower blood pressure. Here, we will delve into the recent clinical trials, market analysis, and projections for this drug.
Clinical Trials and Efficacy
Hypertension Treatment
Verelan PM has been extensively studied in clinical trials for its efficacy in treating hypertension. The usual daily dose is 200 mg administered once daily at bedtime, although doses of 100 mg, 300 mg, and 400 mg have also been evaluated. The antihypertensive effects of Verelan PM are evident within the first week of therapy, and the dose can be titrated upward based on therapeutic efficacy and safety[1][5].
Special Populations
In patients with increased sensitivity to verapamil, such as those with impaired renal or hepatic function, elderly patients, or low-weight patients, an initial dose of 100 mg may be warranted. This cautious approach ensures the safety and efficacy of the treatment[1][5].
Additional Clinical Insights
A recent clinical trial published in JAMA explored the effect of verapamil on pancreatic beta cell function in children and adolescents with newly diagnosed type 1 diabetes. The study found that verapamil partially preserved stimulated C-peptide secretion at 52 weeks from diagnosis, suggesting potential benefits beyond hypertension treatment[4].
Market Analysis
Controlled Release Drug Delivery Market
The global controlled release drug delivery market, which includes drugs like Verelan PM, is projected to grow significantly. By 2028, this market is expected to exceed $90 billion, driven by the advantages of controlled-release technologies such as reduced toxicity, diminished side effects, and maximum precision. These factors are increasing the acceptance of controlled-release drugs among researchers and patients[2].
Market Drivers
The growth of the controlled release drug delivery market is fueled by several factors, including the rising prevalence of chronic diseases, advances in biotechnology, and the introduction of new technologies like blockchain and IoT in supply chain management. The market also benefits from the increasing participation in international clinical research, particularly in regions like India, which offers affordable and highly skilled clinical trial services[2][3].
Market Projections
Global and Regional Forecast
The controlled release drug delivery market is forecasted to see substantial growth globally and regionally. The market is expected to expand due to the increasing demand for innovative therapies and the growing incidence of chronic diseases such as hypertension, diabetes, and multiple sclerosis[2].
Clinical Trial Supplies Market
The clinical trial supplies market, which is closely related to the development and testing of drugs like Verelan PM, is also projected to grow. From $2.70 billion in 2024, this market is expected to reach $4.79 billion by 2033, with a CAGR of 6.58%. This growth is driven by the rising incidence of chronic diseases, tightening regulations, and advances in biotechnology[3].
Advantages and Benefits
Controlled Release Technology
Controlled release technology, as seen in Verelan PM, offers several advantages, including non-toxicity and biocompatibility of the materials used. This technology ensures that the drug concentration in the patient remains within a desired range, reducing side effects and toxicity while providing maximum precision[2].
Patient Compliance
The extended-release formulation of Verelan PM enhances patient compliance by reducing the frequency of dosing. This once-daily administration at bedtime simplifies the treatment regimen, making it easier for patients to adhere to their medication schedule[1][5].
Administration and Safety
Dosage and Administration
Verelan PM capsules should be swallowed whole or, if necessary, the contents can be sprinkled onto applesauce. However, subdividing the contents of the capsule is not recommended. This flexibility in administration can be beneficial for patients who have difficulty swallowing whole capsules[1][5].
Safety and Precautions
The drug comes with specific safety precautions, including contraindications and warnings. For instance, patients with certain heart conditions or those taking specific medications may need to avoid Verelan PM. It is crucial to follow the prescribing information carefully to ensure safe and effective treatment[5].
Key Takeaways
- Clinical Efficacy: Verelan PM is effective in treating hypertension, with antihypertensive effects evident within the first week of therapy.
- Market Growth: The controlled release drug delivery market, including Verelan PM, is projected to exceed $90 billion by 2028.
- Advantages: Controlled release technology offers reduced toxicity, diminished side effects, and maximum precision.
- Patient Compliance: The once-daily extended-release formulation enhances patient compliance.
- Safety: Careful administration and adherence to prescribing information are crucial for safe and effective treatment.
FAQs
What is the usual daily dose of Verelan PM for hypertension?
The usual daily dose of Verelan PM for hypertension is 200 mg administered once daily at bedtime[1][5].
Can Verelan PM be administered in a way other than swallowing the capsule whole?
Yes, the contents of Verelan PM capsules can be sprinkled onto one tablespoonful of applesauce, but it should be swallowed immediately without chewing and followed by a glass of cool water[1][5].
What are the potential benefits of Verelan PM beyond hypertension treatment?
Recent clinical trials suggest that Verelan PM may also have benefits in preserving pancreatic beta cell function in patients with newly diagnosed type 1 diabetes[4].
How is the controlled release drug delivery market expected to grow?
The controlled release drug delivery market is projected to exceed $90 billion by 2028, driven by the rising prevalence of chronic diseases and advances in biotechnology[2].
What are the key drivers of the clinical trial supplies market growth?
The clinical trial supplies market is driven by the rising incidence of chronic diseases, tightening regulations, and advances in biotechnology, with a projected growth to $4.79 billion by 2033[3].
Sources
- Drugs.com: Verelan PM Dosage Guide.
- Businesswire: Global Controlled Release Drug Delivery Market Research Report 2022.
- GlobeNewswire: Clinical Trial Supplies Industry Forecast Report 2025-2033.
- PubMed: Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes.
- Drugs.com: Verelan PM: Package Insert / Prescribing Information.
